WeHealth by Servier, the e-health department of Servier Group, and PathMaker Neurosystems, have announced the closing of a partnership agreement to develop and commercialise the first neuromodulation technology for non-invasive treatment of spasticity. The agreement between WeHealth and PathMaker establishes an exclusive world-wide distribution arrangement, excluding the USA and Japan, for PathMaker’s MyoRegulator device.
As part of the agreement, WeHealth will fund a recently initiated European clinical trial evaluating MyoRegulator for non-invasive treatment of spasticity secondary to stroke, which is currently being conducted by France’s prestigious Brain and Spine Institute (Institut du Cerveau et de la Moelle Epinière – ICM) at the Pitié-Salpêtrière Hospital in Paris. WeHealth will also fund a larger European clinical trial intended to support reimbursement coverage. PathMaker will receive an upfront payment, clinical/regulatory milestones and commercial royalties from future sales of the device and disposables (single-use electrodes) in the Servier territories.
“We are excited by WeHealth’s commitment to advancing next-generation treatments for chronic neuromotor conditions,” said Nader Yaghoubi, president and CEO of PathMaker. “This partnership will provide a large number of patients with access to this non-invasive treatment through WeHealth’s international presence in more than 100 countries worldwide.”
“The MyoRegulator device has clear benefits for patients with serious neurological conditions. Our partnership with PathMaker represents an opportunity for WeHealth to contribute to the advancement of a novel technology that is moving the field of bioelectronic medicine forward,” said David Guez, general director of WeHealth by Servier.